Validated methods for assessment of subclinical atherosclerosis in rheumatology

G Kerekes, P Soltész, MT Nurmohamed… - Nature Reviews …, 2012 - nature.com
Rheumatoid arthritis, as well as other types of arthritides and connective tissue diseases, is
associated with accelerated atherosclerosis, and increased cardiovascular morbidity and …

Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do

Z Szekanecz, G Kerekes, E Végh, Z Kardos… - Autoimmunity …, 2016 - Elsevier
Autoimmune-inflammatory rheumatic diseases, such as rheumatoid arthritis (RA) have been
associated with autoimmune atherosclerosis leading to increased cardiovascular risk …

[HTML][HTML] Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis

K Gulyás, Á Horváth, E Végh, A Pusztai… - Clinical …, 2020 - Springer
Objectives Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated
with generalized and localized bone loss. We conducted a comprehensive study using …

Pharmacogenetics and pharmacogenomics in rheumatology

Z Szekanecz, B Meskó, S Poliska, A Váncsa… - Immunologic …, 2013 - Springer
Pharmacogenetics and pharmacogenomics deal with possible associations of a single
genetic polymorphism or those of multiple gene profiles with responses to drugs. In …

[HTML][HTML] Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis

A Hamar, Z Szekanecz, A Pusztai, M Czókolyová… - Osteoporosis …, 2021 - Springer
Janus kinase (JAK) inhibitors are used to treat rheumatoid arthritis (RA). We assessed the
effects of tofacitinib on bone density and bone markers in association with clinical and …

Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept

É Rákóczi, B Perge, E Végh, P Csomor, A Pusztai… - Joint Bone Spine, 2016 - Elsevier
Objectives To prospectively evaluate the immunogenicity of a 13-valent conjugated
pneumococcal vaccine (PCV13) in rheumatoid arthritis (RA) patients undergoing etanercept …

[HTML][HTML] Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis

E Végh, G Kerekes, A Pusztai, A Hamar… - Rheumatology …, 2020 - Springer
Accelerated atherosclerosis, increased cardiovascular morbidity and mortality have been
associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Vascular function …

[HTML][HTML] Salivary citrullinated proteins in rheumatoid arthritis and associated periodontal disease

I Tar, É Csősz, E Végh, K Lundberg, N Kharlamova… - Scientific Reports, 2021 - nature.com
Periodontal disease (PD) can be an important precipitating factor in the production of
citrullinated proteins. Its importance is emphasized, but it is not the only way to produce …

Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment …

A Váncsa, Z Szabó, S Szamosi, N Bodnár… - The Journal of …, 2013 - jrheum.org
Objective. To assess the efficacy and safety of longterm rituximab (RTX) therapy for
rheumatoid arthritis (RA) and study correlations among B cell depletion, clinical response …

[HTML][HTML] Changes of metabolic biomarker levels upon one-year anti-TNF-α therapy in rheumatoid arthritis and ankylosing spondylitis: associations with vascular …

M Czókolyová, A Pusztai, E Végh, Á Horváth… - Biomolecules, 2021 - mdpi.com
Background: Cardiovascular (CV) morbidity, mortality, and metabolic syndrome are
associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Here, lipids and …